Immunoreactivity of boronated antibodies.
Boronated antibodies have already been evaluated as agents in neutron capture therapy. Because the boronation procedure may alter the properties of the antibody it is important to study the immunoreactivity of the conjugated antibody before in vivo use. In our studies of two dextran-boronated monoclonal antibodies, anti-glial fibrillary acidic protein antibody, and anti-hyaluronectin antibody, we have used ELISA and immunohistological methods to determine antibody activity and specificity. A ten-fold decrease in activity was observed for both antibodies in ELISA, and non-specific interactions were seen in both immunohistological and ELISA procedures. The boron compound used was shown to be at least partly responsible for these non-specific interactions.
Molecular Oncology Department, Centre H. Becquerel, Rouen, France.
M L
ML
Pettersson
M N
MN
Courel
N
N
Girard
R
R
Abraham
D
D
Gabel
M
M
Thellier
B
B
Delpech
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000918:Antibody Specificity; D001895:Boron / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005904:Glial Fibrillary Acidic Protein / Q000276:immunology; D018960:Hyaluronan Receptors; D007074:Immunoglobulin G / Q000276:immunology; D051379:Mice
D000911:Antibodies, Monoclonal; D002352:Carrier Proteins; D005904:Glial Fibrillary Acidic Protein; D018960:Hyaluronan Receptors; D007074:Immunoglobulin G; D001895:Boron